How is a levothyroxine (T4) solution prepared using Ora-Sweet (oral sweetening agent) or Ora-Plus (oral suspending agent)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 18, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Research

To prepare a levothyroxine solution using Ora-Sweet or Ora-Plus, mix crushed levothyroxine tablets with a 1:1 ratio of Ora-Sweet and Ora-Plus to create a 25 mcg/mL suspension, as this method has been shown to be effective in clinical practice 1.

Preparation Steps

  • Crush the required number of tablets to achieve the desired concentration, for example, ten 100 mcg tablets to make 40 mL of a 25 mcg/mL solution.
  • Triturate the crushed tablets with a small amount of the vehicle to form a smooth paste, then gradually add more vehicle while mixing until you reach the final volume.
  • The resulting suspension should be stored in an amber glass bottle, refrigerated, and used within 14 days, as the stability of levothyroxine sodium in oral liquid dosage forms has been studied and found to be most stable under these conditions 2.

Key Considerations

  • Shake well before each use to ensure uniform distribution of the medication.
  • This compounded preparation is necessary because levothyroxine is unstable in solution and commercially available liquid formulations are limited.
  • The acidic nature of Ora-Sweet helps preserve the medication while Ora-Plus provides suspension stability.
  • Always label the container with preparation date, expiration date, storage requirements, and dosing instructions.
  • Remember that compounded preparations may have variable potency compared to commercial products, so careful monitoring of thyroid function tests is recommended when using this formulation, as supported by recent studies on the use of liquid and softgel levothyroxine formulations 3, 4, 5.

References

Research

Stability of an extemporaneously compounded levothyroxine sodium oral liquid.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 1996

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.